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goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
Introduction
Malignant pleural mesothelioma (MPM) is a rare and highly lethal cancer associated with exposure to asbestos. In the Surveillance, Epidemiology, and End Results database, MPM peaked in the 1980s to 1990s and is now plateauing. In men, the incidence has been stable at 1.8 cases per 100,000 for the past 10 years, with peak values in the early 1990s (2.5 cases per 100,000), whereas in women, the rate has been 0.4 cases per 100,000 and has not changed substantially over time.
1,2 However between 1999 and 2015, the overall rates of death due to mesothelioma continued to increase. 3 Women with MPM have a threefold better 5-year survival rate than men. 4 There are more than 400 fibrous minerals present in nature, but regulatory organizations have identified only six asbestos mineral fibers that have widespread commercial use and are carcinogenic. 5 Although occupational exposure to asbestos has been greatly reduced in industrial nations, development of rural areas has led to an increase in environmental exposure to asbestos and other fibers such as erionite. 2, 6, 7 In recent years, a considerable proportion of mesothelioma cases have had no identifiable source of asbestos exposure, suggesting that traditional questionnaires do not properly identify sources of environmental exposure and that improved biomarkers of exposure are needed. Additionally, an inherited predisposition to mesothelioma, as well as to several other cancers, has been associated with germline alterations in BRCA-associated protein-1 gene (BAP1). 8 This supports a potential standard role for germline genetic profiling in patients with BAP1-mutated tumors.
As MPM is an orphan disease, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer (IASLC), and Mesothelioma Applied Research Foundation (MARF) organized the NCI-IASLC-MARF Mesothelioma Clinical Trials Planning Meeting (CTPM) to focus on identifying knowledge gaps and designing at least two or three practice-changing multimodality clinical trials that would be perfomed through the NCI's National Clinical Trials Network (NCTN). A group of basic scientists, clinicians (specializing in radiology, pulmonary medicine, thoracic medical oncology, thoracic surgery, thoracic radiation oncology, and pathology), epidemiologists, and patient advocates and representatives of the U.S. Food and Drug Administration (FDA) convened in Bethesda, Maryland, to participate in the panel discussions. This subsequent article details the discussion and recommendations from the NCI-IASLC-MARF Mesothelioma CTPM.
Background Genomics of Disease
MPM is largely characterized by loss of tumor suppressor genes. Genomic studies have demonstrated that except for mutations in BAP1 and cyclin dependent kinase inhibitor 2A gene (CDKN2A), driver mutations are rare in mesothelioma. [9] [10] [11] [12] However, recent studies 12 have revealed that minute deletions (i.e., DNA deletions <3 kb) are frequent in mesothelioma and are often missed by comparative genomic hybridization arrays and next-generation sequencing. Therefore, it is likely that current genomic information underestimates the true incidence of genetic mutations and tumor suppressor gene inactivation in mesothelioma. 12 The Cancer Genome Atlas mesothelioma program integrated exome sequencing, copy number, gene expression, noncoding RNA (microRNA and long noncoding RNA) expression, DNA methylation, and proteomic data from 74 chemonaive patients with MPM and identified histologyindependent prognostic subtypes and reported that a high epithelial-mesenchymal transition score, mesothelin promoter methylation, deletion of CDKN2A, and upregulation of the Ras-mitogen-activated protein kinase and phosphoinositide 3-kinase/mechanistic target of rapamycin (mTOR) signaling pathways all adversely affect survival. 13 Although there are many MPM cell lines available for biological and preclinical studies, the efforts to establish patient-deriived xenograft (PDX) models from MPM have been limted. 14 Wu et al. 15 successfully established a PDX from 20 of 50 surgically obtained MPM tumors (40%) by implanting them subcutaneously into nonobese diabetic/ severe combined immunodeficient (NOD-SCID) mice and serially passaged them for up to five generations. Histological and biomarker profiles (including BAP1 and CDKN2A status) of the PDX models closely resembled those of the parent tumors, and genomic aberrations found in these models recapitulated previously reported changes. Incorporating PDX development as a translational correlate in clinical trials would be beneficial in advancing the field.
Background Therapies in Early-Stage MPM
Although there is no level I evidence to support surgery for MPM, some patients benefit from a surgery-based approach, especially those with an epithelioid subtype, lower-volume disease, and/or minimal to no nodal involvement. 16 The optimal outcome of MPM surgery is a macroscopic complete resection, with either lung-sparing or lung-sacrificing surgery. Whereas lung-sacrificing surgery has been clearly defined and highly standardized as an extrapleural pneumonectomy (EPP), efforts to standardize the technique for lung-sparing have been limited by lack of randomized trials. In the absence of data, various combinations of extended surgery performed by pleurectomy/decortication (P/D) have recently emerged.
Currently, there is no consensus regarding the optimal multimodality approach to patients with resectable MPM. 17 As complete surgical resection (R0 resection) remains elusive in most patients with MPM, local recurrence represents the most common form of disease relapse. To address this, many places throughout the world use multimodality therapy with neoadjuvant or adjuvant chemotherapy and radiation despite the lack of evidence-based data from randomized trials. Some experts also believe that additional intraoperative cytoreductive treatment can decrease local recurrence rates. Various intraoperative treatments under investigation include hyperthermic chemotherapy lavage (typically cisplatin with or without other agents), hyperthermic povidone iodine lavage, fibrinassociated cisplatin (applied as a spray), and photodynamic therapy. Photodynamic therapy 18 is currently the only modality being studied in a phase II randomized clinical trial (NCT02153229). Broad surface cautery using the argon beam coagulator and/or Aquamantys bipolar cautery (Medtronic, Minneapolis, MN) also continues to be studied, as does cryotherapy as intraoperative adjuvant therapy (NCT02464904). Given the accessibility of mesothelioma, local immunotherapy and intrapleural gene therapy (NCT01997190) are also being investigated in mesothelioma. 19, 20 Radiotherapy (RT) is used in the management of MPM in the adjuvant, neoadjuvant, and palliative settings. It is standard practice to deliver adjuvant conventially fractionated RT (50-60 Gy) to the ipsilateral hemithorax in patients who receive an EPP. 21, 22 Neoadjuvant accelerated hemithoracic intensity-modulated RT (IMRT) before EPP has recently emerged as a viable treatment approach and is associated with longterm disease control and survival in clinically nodenegative patients. 23, 24 This approach of five fractions of 5 to 6 Gy each relies on the complete resection of the lung shortly after the completion of RT to avoid the risk of life-threating radiation pneumonitis of the ipsilateral lung. This approach remains experimental at this time and is offered only at certain centers.
In patients who receive lung-sparing operations, there is no standard recommendation for adjuvant RT because of the potential high risk of radiation pneumonitis. Recently, adjuvant hemithoracic pleural radiation therapy to 50 to 60 Gy in conventional fractionation was found to be safe, feasible, and efficacious at centers with experience in using this complex RT technique. [25] [26] [27] Arc therapy, which is an advanced form of IMRT that delivers precisely sculpted three-dimensional dose distribution with 360-degree rotation of the gantry in a single-arc or multiarc treatment, may further improve normal tissue dosimetry and target coverage. 28 Additional randomized trials to study this technology are needed to demonstrate efficacy and clinical benefit before it can be adopted as standard practice.
Advanced RT techniques may further facilitate novel roles for RT in the treatment of MPM, including whole pleural RT using proton therapy after P/D, 29 stereotactic body radiation therapy for isolated recurrences alone or in combination with immunotherapy (NCT03399552, NCT02959463), and even the use IMRT or proton therapy to definitively target all gross disease.
Advances in systemic therapy are clearly needed in this space. Neoadjuvant window-of-opportunity trials investigating novel therapies 30 have shown such approaches to trial design to be feasible, and several trials are currently investigating immunotherapies (NCT02592551, NCT02707666, and NCT02959463). The SWOG S1619 trial (NCT03228537) is evaluating neoadjuvant cisplatin-pemetrexed-atezolizumab. In the adjuvant space, interventions with vaccines may have promise. Galinpepimut-S Wilms tumor 1 vaccine was randomized against placebo in a double-blind trial 31 ; when administered after macroscopic complete resection, the vaccine demonstrated superiority over control. The median progressionfree survival (PFS) was 7.4 months versus 10.1 months, and the median overall survival (OS) was 18.3 months versus 22.8 months in the control and vaccine arms, respectively. 31 
Consensus Panel on Future Early-Stage MPM Clinical Trials
The Consensus Early Stage Panel highlighted several limitations to future trial designs and recommended that firm standardization guidelines be published ahead of opening any NCTN studies. The following recommendations were offered to advance the field: (1) mesothelioma surgical trials should ideally be randomized, be conducted in limited institutions that have the ability to standardize surgical practice, collect data reliably, obtain patient-reported outcomes (PROs), perform the required translational correlates, and provide adequate safety for patients in a tertiary/quaternary care center; (2) a stable platform for surgical technique is needed, with standardization of required preoperative procedures (e.g., contrast computed tomography [CT], positron emission tomography [PET]-CT, and mediastinal sampling [endobronchial ultrasound, endoscopic ultrasound, mediastinoscopy, and peritoneal assessment with laparoscopy]), determination of which types of surgeries to perform, definition of what constitutes a "resectable" patient, identification of the standard follow-up period and interval, and specification of the necessary reporting components in all trial operative reports); (3) uniformity in pathologic reporting is also needed to denote the necessary reported components, define a core panel of biomarkers that should be conducted on the trial, and standardize specimen collection techniques for blood/pleural effusion/tumor tissue; (4) imaging techniques remain a major challenge because few radiologists are familiar with how to conduct assessment using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in mesothelioma; as a result, an IASLC webinar is suggested to educate investigators on standard radiographic reporting, and discussion of the role of volumetric CT as a future potential improved measurement system is needed; (5) NCTN trials evaluating the sequence of trimodality and bimodality therapy are still needed, as are surgical comparator trials (EPP versus P/D) and RT trials (P/D with and without IMRT), although the feasibility of such trials is still debatable; and (6) window-of-opportunity trials are needed to collect data for translational studies, but the variability in surgical techniques and intraoperative adjunctive therapies need to be standardized first, in addition to which, any involved centers conducting these complicated studies would need to be accredited (as in American College of Surgeons Oncology Group trials).
Background Therapies in Unresectable MPM
To date, the only FDA-and European Medicines Agencyapproved frontline regimen in unresectable MPM is cisplatin-pemetrexed. 32 Platinum-pemetrexed for four to six cycles of therapy is commonly used throughout the world.
Antiangiogenics
Angiogenesis inhibitors are among the most widely studied agents for treating mesothelioma. Although minimal activity was observed in several single-arm phase II studies [33] [34] [35] [36] [37] [38] [39] [40] [41] of monotherapy vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, the Mesothelioma Avastin Cisplatin Pemetrexed Study trial demonstrated a survival benefit with the addition of bevacizumab to cisplatin-pemetrexed. 42 The addition of bevacizumab yielded a superior median PFS of 9.2 45 The LUME-Meso trial, 46 which was a randomized phase II trial investigating pemetrexed/cisplatin plus placebo or nintedanib (VEGF receptor, platelet derived growth factor receptor, and fibroblast growth factor receptor inhibitor), demonstrated that the triplet regimen improved response rates (57% versus 44%) and resulted in a higher median PFS (9. 4 46 The ongoing phase III LUMEMeso trial recently completed accrual and is limited to patients with epithelioid mesothelioma, representing the subgroup of patients who benefited the most from the addition of nintedanib in the phase II study. 46 
Novel Targeted Agents
Despite recent advances in personalized therapies for cancer, genetic and epigenetic predictive biomarkers are only beginning to emerge for mesothelioma. After identification of argininosuccinate synthetase 1 loss in mesothelioma, which leads to arginine auxotrophy, the ADAM trial demonstrated that the arginine depletor pegylated adenosine deiminase is active in argininosuccinate synthetase 1-deficient mesothelioma. 47 This finding, as well as promising data from the TRAP trial (NCT02029690) combining pegylated adenosine deiminase with chemotherapy, 48 led to a registration phase III trial, ATOMIC-Meso (NCT02709512), focusing on biphasic and sarcomatoid disease.
BAP1 is a frequently inactivated tumor suppressor gene in mesothelioma that up-regulates the epigenetic silencing machinery regulated by enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2). 49 Inhibition of EZH2 is synthetic lethal to BAP1-negative tumors, and a phase II multicenter trial using EZH2 inhibitor tazemetostat (NCT 02860286) recently completed accrual. BAP1 loss also leads to homologous repair deficiency, suggesting that poly(ADP-ribose) polymerase 1 inhibition may be more active in this genetic subgroup. Accordingly, a proof of concept study is currently being developed.
CDKN2A is frequently deleted in mesothelioma, leading to loss of p14ARF and p16INK4A. 50 Large scale drug-gene interaction screens have identified cyclindependent kinase 4/6 inhibition as being active in CDKN2A-negative tumors, 51 warranting a phase II proof of concept study that is currently in development.
The spindle poison vinorelbine exhibits some activity in relapsed mesothelioma [52] [53] [54] and the randomized Vinorelbine in Mesothelioma trial (NCT 02139904) aims to evaluate loss of the essential, spindle assembly checkpoint regulator use BRCA1 as a predictive biomarker of de novo resistance.
Finally, inactivation of neurofibromin 2 (which encodes Merlin) has been proposed to be synthetic lethal with focal adhesion kinase inhibition 55 ; however, this was not borne out in the COMMAND trial (NCT01870609). Similarly, phosphoinositide 3-kinase/mTOR inhibition has shown modest efficacy. 56 Other approaches to exploit neurofibromin 2 aberrations, such as neural precursor cell expressed, developmentally down-regulated 8 inhibition, especially in combination with mTOR blockade, 57 may be more promising and a proof of concept study (NCT03319537) is under way.
Immunotherapies
The immune system may be an important therapeutic target in MPM, as evidenced by the positive prognostic impact of tumor-infiltrating lymphocytes, 58, 59 the reports of spontaneous regression of mesothelioma, 60, 61 and responses to immunotherapy in patients. 62, 63 High programmed death ligand-1 (PD-L1) immunohistochemical expression has been associated with a negative prognosis 64, 65 and may have predictive capability with regard to checkpoint inhibitors in MPM. 62, 63 However, this biomarker has several limitations; there are emerging data indicating that PD-L1 expression is heterogeneous and dynamic in many tumor types, including mesothelioma. 66, 67 This supports continued translational efforts to comprehensively profile the local immunologic environment and to incorporate these data with genomic, transcriptomic, proteomic, demographic, and outcome data, as has been done in other malignancies such as lung cancer. 68, 69 Immunotherapies are under active investigation in the salvage and frontline space. In the salvage space, the DETERMINE study utilizing the cytotoxic T-lymphocyte associated protein 4 inhibitor tremelimumab demonstrated no benefit over placebo. 70 In contrast, single-arm clinical trials targeting programmed death (PD-1) or PD-L1 have shown response rates ranging from 10% to 20% and a small proportion of long-term responders. 62, 63 Confirmation of these results is under way in randomized phase III trials of single-agent immunotherapy against placebo (CONFIRM, NCT03063450) or chemotherapy (PROMISE, NCT 02991482). Ongoing combination strategies include combining PD-1/PD-L1 inhibitors with anti-cytotoxic T-lymphocyte associated protein 4 (tremelimumab-durvalumab, nivolumab-ipilimumab) in the first or second line, or anti-VEGF or focal adhesion kinase or AXL receptor tyrosine kinase inhibition in the relapsed setting. The Mesothelioma Avastin Cisplatin Pemetrexed Study II trial (NCT02716272), which evaluated two parallel arms of nivolumab and nivolumab with ipilimumab, reported a 27.8% objective response rate (ORR), 50% disease control rate, and median PFS of 5.6 months with the ipilimumab-nivolumab arm. 62 These data led to the addition of pembrolizumab (with PD-L1 expression 1%) and nivolumab with and without ipilimumab to the National Comprehensive Cancer Network guidelines. 43 In the frontline space, checkpoint inhibitors are being studied in combination with chemotherapy or compared against chemotherapy (NCT02899299).
With increasing evidence that higher effector T-cell responses can improve survival in mesothelioma, 71 adoptive cell therapy using mesothelin (a cancer cell surface antigen) targeted chimeric antigen receptortransduced T cells has been translated to phase I clinical trials with administration both intrapleurally (NCT02414269) and systemically (NCT03054298). PD-1/PD-L1 checkpoint blockade agents have augmented functional persistence of chimeric antigen receptor T cells in preclinical models. 72 Several other mesothelin-targeted therapies, including antimesothelin immunotoxin (LMB-100) and antibody-drug conjugates targeting mesothelin (anetumab ravtansine), are currently in clinical trials either as a single agent or in combination with chemotherapy or immunotherapy. 73 The reduced immunogenicity antimesothelin immunotoxin LMB-100 is currently being evaluated in phase I/II studies for treatment of patients with treatment-refractory pleural and peritoneal mesothelioma. 74 In a phase I clinical trial, anetumab ravtansine showed promising efficacy for advanced disease. 75 However, in a randomized phase II trial of second-line therapy, there was no difference in PFS between anetumab ravtansine and vinorelbine. 76 Ongoing studies are evaluating anetumab ravtansine plus pemetrexed and cisplatin in mesothelioma (NCT02639091).
Consensus Panel on Future Unresectable MPM Clinical Trials
The metastatic panel discussion focused on trial designs for NCI sponsorship. Several proposed trials were offered, and recommendations and conclusions from the panel included the following: (1) all future NCTN mesothelioma trials should collect translational correlates before and during (ideally) study treatment as well as after disease progression; (2) translational correlates should include specimens from blood, pleural effusion, and tumor (primary and metastatic); (3) standard operating procedures for collection techniques for all biospecimens are needed and should be applied to all future NCTN mesothelioma trials; (4) metastatic clinical trials require careful consideration of the end points given the current limitations in radiographic reporting (although OS is the criterion standard, the required large sample size remains challenging for mesothelioma studies); (5) additional obstacles to successful mesothelioma NCTN studies include limited accrual of patient numbers, thus emphasizing the need for more reasonable and lenient inclusion/exclusion criteria; (6) critical components for future NCTN trial design include avoiding replication with pharmaceutical studies and focusing on scientific questions instead of on regulatory drug development; (7) reproducing a single center's trial experience (i.e., neoadjuvant chemoradiation or IMRT after lung-sparing surgery) in a multicenter environment to standardize or validate a therapy is a reasonable strategy; (8) PROs are critical components to all studies (mesothelioma-specific PROs are under development and will require validation, potentially in NCTN trials); and (9) the IASLC could potentially be the primary site for a large international clinical database for mesothelioma.
Consensus Panel on Translational Correlates in MPM Trials
The investigation of noninvasive, possibly blood-and pleural fluid-based biomarkers for the early detection, diagnosis, prognostication, and monitoring of disease response should be incorporated into any and all prospective screening or therapeutic protocols. The lack of large prospective well-defined cohorts of patients with MPM with annotated samples collected in a uniform manner has contributed to an inability to validate several potential screening markers such as serum/plasma microRNAs, [77] [78] [79] [80] fibulin-3, 81-84 and high mobility group box 1, 85-88 among others. 2, 89 Presently, mesothelin is the only serum biomarker that has received FDA approval (humanitarian device exemption) for monitoring patients with epithelioid and biphasic mesothelioma. However, clinical trials sponsored by the NCI Early Detection Research Network and Department of Defense are being conducted to validate high mobility group box 1 as a biomarker of asbestos exposure and mesothelioma and fibulin as a biomarker for mesothelioma.
The CTPM group recommended that sample collections be standardized and include both cellular and noncellular components of the blood and pleural fluid, including serum, plasma, buffy coat, and peripheral blood mononuclear cells, as well as pleural cells and pleural fluid. Moreover, the sample collections must follow standardized operating procedures to ensure ideal conditions for exosome and microvesicle harvest and fluids that can be used for cell-free DNA and next-generation sequencing. Decisions regarding the use of citrate, ethylenediaminetetraacetic acid, or heparin tubes and/or the use of PAXgene RNA/DNA tubes should be part of the discussion, and if needed, samples should be collected using various anticoagulants and specialized collection tubes.
In surgical patients, collection should include blood and pleural fluid, fresh tumor samples for flow analysis after digestion, snap-frozen tumor with control tissue, and fixed samples for future studies. Given the heterogeneity of mesothelioma, samples from several areas of the tumor should be considered. When the microenvironment of either the tumor or the pleural fluid is being investigated, appropriate control "uninvolved" mesothelium should be made available from surgical cases. It is very important to recognize that pleural fluid from these patients remains a rich source for cell line development, microenvironment studies, and standardized proteomic or genomic platform investigations.
The application of next-generation sequencing technologies has the potential to identify gene expression patterns that predict responses to immunotherapy or select novel synergistic drug combinations. 90 Furthermore, specific mutations within mesothelioma tumors detected by similar techniques may also lead to the development of mutation-directed immunotherapies such as personalized vaccine strategies. 91, 92 For the translational correlates of any prospective trials to yield meaningful information, the approach must standardize collections, processing, and storage of specimens and also incorporate compulsive documentation of patient demographics, all in a way that will facilitate seamless adoption by the international community.
Consensus Panel on Radiographic Assessments in MPM Clinical Trials
Radiographic assessment of mesothelioma, even in large academic centers, is inadequate and possibly inconsistent for clinical trials. 93 Magnetic resonance imaging and fludeoxyglucose PET-CT demonstrate incremental advantages over CT scans, which are clinically relevant in some settings. Magnetic resonance imaging is more useful in determining resectability by providing better anatomical detail and potential to provide information on angiogenesis, whereas CT scans have stronger value in assessing treatment response in patients undergoing systemic therapy and potentially providing prognostic information. [94] [95] [96] [97] Clinical staging in MPM is of limited value for clinical trials on account of high interobserver variability from its dependence on qualitative assessment of several of the T-stage descriptors, such as involvement of the visceral pleura, lung parenchyma, and diaphragm muscle, which cannot be reliably predicted by any imaging modality. 98 Measurement of tumor volume on cross-sectional imaging has emerged as a potential quantitative tool with prognostic significance and is being evaluated as a surrogate of T category in clinical staging. [99] [100] [101] Response assessment is prone to a high degree of intraobserver variability because of the complex rind-like morphology of this tumor. This challenge prompted the development of mesothelioma-specific modified RECIST criteria. 102 Although widely used, these criteria remain limited in their ability to uniformly assess disease. Measurement of tumor volume has shown prognostic significance at a volume cutoff at of 500 cm 2 and can therefore serve a dual purpose: staging patients and more accurately quantifying therapeutic response in prospective clinical trials. 99, 101, 103 Additional studies are needed to compare measurements of tumor volume with the established response criteria to refine the cutoffs for categorization of response. Undoubtedly, it is imperative that imaging and reporting protocols be homogenized across centers to allow pooling of data in this rare disease and also facilitate development of standardization metrics that will transition tumor volume into clinical practice.
Consensus Panel on End Points for MPM Clinical Trials
The criterion standard end point for definitive trials in advanced mesothelioma is a demonstration of improvement in OS. 104 Pemetrexed, which is the only systemic treatment approved in mesothelioma, was approved in 2004 on the basis of an improvement in OS when combined with cisplatin compared with cisplatin alone. 32 Other end points that are typically used in oncology drug development trials for advanced disease are tumor-based end points assessed radiographically, such as ORR, duration of response, and PFS. In this uniquely pleural-based disease, these end points are challenging. The modified RECIST criteria for mesothelioma may be acceptable to assess ORR and PFS for use in trials testing new agents, but given their limitations and challenges, central radiographic review is crucial. Additionally, PFS would be interpretable only in randomized clinical trials with a large magnitude of treatment effect to overcome the uncertainties surrounding assessment of this radiographic end point. Development of innovative alternative end points is needed.
Consensus Panel on PROs in MPM Clinical Trials
Malignant mesothelioma requires the administration of aggressive forms of therapy, which can result in a decrease in health-related quality of life (QOL). In some rare instances, these negative by-products may provoke noncompliance or refusal by the patient to receive subsequent chemotherapy treatments. To date, QOL studies have been limited to report only symptoms that occur during treatment. The Lung Cancer Symptom Scale adapted to mesothelioma (Meso-LCSS questionnaire), which has been used in several large studies 42, 70, 105 is criticized for its lack of a comprehensive approach to the disease. In terms of the data collected, it does not reach the scope that mesothelioma experts and patients would like to obtain. The Patient Quality of Life Questionnaire Physical and Emotional, which is under development at Columbia University Medical Center, offers a comprehensive evaluation of QOL by using six different aspects of an individual's life. As treatments become more advanced and research reveals the substantial connections between physical activity, emotional well-being, and physical well-being, investigators will need innovative comprehensive tools to evaluate the QOL of study participants.
Consensus Panel Conclusion and Future Trial Recommendations
In conclusion, the NCI-IASLC-MARF Mesothelioma CTPM established several recommendations for future strategies in NCTN mesothelioma clinical trials (Fig. 1) . The main themes emphasized the need for generating science; avoiding duplicative trials that are already on industry drug development pathways; including multidisciplinary studies; standardizing surgical, radiation, and radiographic techniques; and always including translational and quality of life components. It was advised that the next national mesothelioma trials should avoid complexity and focus on the feasibility of standardizing surgical/radiation techniques and biospecimen sample collection, as well as on demonstrating reproducibility in multiple centers. The participants agreed on supporting two potential NCTN trials, one using IMRT after lung-sparing surgery and a second metastatic study (Meso-MATCH) harnessing known targets and pairing treatments along with immunotherapies. In addition, several future efforts focused on publishing standardized guidelines for surgical, radiographic, translational research, QOL/PROs, and radiation oncology techniques will be undertaken.
